Know what you are comparing.
These examples explain different treatment categories. They are not a list of medications currently available through our program. A clinician determines the appropriate indication, formulation and dose.
SEMAGLUTIDE / ORAL OPTIONWegovy® tablets
An oral prescription weight-management option for eligible patients. The pill and injection have different dosing instructions.
Official product information ↗
SEMAGLUTIDE / INJECTABLE OPTIONWegovy® injection
A prescription option for weight management when appropriate. The specific presentation and dose require clinical review.
Official product information ↗
TIRZEPATIDE / INJECTABLE OPTIONZepbound®
A GIP/GLP-1 prescription treatment with an approved weight-management indication for eligible patients.
Official product information ↗
TIRZEPATIDE / VIALZepbound® vial
Manufacturer product image. The prescribed format and availability require clinical and pharmacy confirmation.
Official product information ↗Different brands,
different labels.
Ozempic® and Mounjaro® are diabetes medicines. Do not treat them as interchangeable with another brand simply because an ingredient overlaps.
Always review the prescribed product’s current labeling with your clinician.
GLP-1 medicines have important contraindications, side effects and interactions. Review the full prescribing information and Medication Guide before treatment. Do not combine products or change your dose without prescriber guidance.
Compounded options are different.
Compounded semaglutide and tirzepatide are not FDA-approved. They should not be described as equivalent to approved branded products. An individual clinical need, applicable requirements and pharmacy review determine whether a compounded option can be considered.
Costs & access
Retail pricing, insurance coverage and program availability have not been confirmed. Before payment, patients should receive the medication name, formulation, pharmacy and a complete cost breakdown.
